Status:
RECRUITING
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
Lead Sponsor:
Australian Catholic University
Collaborating Sponsors:
St Vincent's Hospital Melbourne
The University of Queensland
Conditions:
Obesity
Type 2 Diabetes Mellitus (T2DM)
Eligibility:
All Genders
18+ years
Brief Summary
An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionna...
Detailed Description
Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will...
Eligibility Criteria
Inclusion
- Aged 18+ years old
- Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
- The primary reason for commencing the medication will be for diabetes or weight management
- Willing to participate in dietary recall and questionnaires
Exclusion
- Aged under 18 years,
- used a GLP-1 agonist medication in the previous 6 months,
- unwilling or unable to provide dietary recalls
- non-English speaking.
Key Trial Info
Start Date :
May 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 22 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07001553
Start Date
May 28 2025
End Date
December 22 2025
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Australian Catholic University
Fitzroy, Victoria, Australia, 3065